Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and for the month of July.
Ascendis Pharma A/S (NASDAQ: ASND) is expected to present full Phase 1 data from its TransCon-PTH hypoparathyroidism treatment later this month. Shares of Ascendis closed Friday at $66.52, with a consensus analyst target price of $84.66 and a 52-week trading range of $25.50 to $76.29.
Epizyme Inc. (NASDAQ: EPZM) is expected to issue an update on its partial clinical hold of tazemetostat following reports of a child with advanced poorly differentiated chordoma, a rare bone cancer, developing a secondary T-cell lymphoma. Trial enrollment outside the United States has not been affected. Shares of Epizyme closed Friday at $13.55, in a 52-week range of $11.15 to $21.40 and with a consensus analyst target of $25.25.
Omeros Corp. (NASDAQ: OMER) is expected to release data from its Phase 2 study of OMS721/IgAN in patients not taking steroids (U.S. cohort). Shares of Omeros closed Friday at $18.14. The consensus analyst target is $36.40, and the 52-week range is $8.36 to $25.20.
Tesaro Inc. (NASDAQ: TSRO) is expected to issue an update on its regulatory discussions with FDA regarding niraparib in breast cancer. Shares of Omeros closed Friday at $44.47, with a consensus analyst target of $77.67 and a 52-week range of $38.40 to $143.45.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.